Axsome Therapeutics Inc (NASDAQ:AXSM) had its Buy rating reiterated by HC Wainwright with a $18.00 price target

Axsome Therapeutics Inc (NASDAQ:AXSM) had its Buy rating reiterated by HC Wainwright with a $18.00 price target

Mar 15, 2019 (Market Exclusive via COMTEX) —

Analyst Ratings For Axsome Therapeutics Inc (NASDAQ:AXSM)

Today, HC Wainwright reiterated its Buy rating on Axsome Therapeutics Inc (NASDAQ:AXSM) with a price target of $18.00.

There are 4 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.

The current consensus rating on Axsome Therapeutics Inc (NASDAQ:AXSM) is Buy with a consensus target price of $24.75 per share, a potential 131.09% upside.

Some recent analyst ratings include

3/15/2019-Axsome Therapeutics Inc (NASDAQ:AXSM) had its Buy rating reiterated by HC Wainwright with a $18.00 price target 1/7/2019-Axsome Therapeutics Inc (NASDAQ:AXSM) had its Buy ➝ Positive rating reiterated by LADENBURG THALM/SH SH with a $45.00 price target 6/20/2017-Axsome Therapeutics Inc (NASDAQ:AXSM) had its Buy rating reiterated by Aegis with a $20.00 price target On 6/19/2018 Nick Pizzie, CFO, bought 31,000 with an average share price of $3.10 per share and the total transaction amounting to $96,100.00. On 12/23/2015 Randall Kaye, Insider, bought 1,000 with an average share price of $9.03 per share and the total transaction amounting to $9,030.00.

About Axsome Therapeutics Inc (NASDAQ:AXSM)
Axsome Therapeutics, Inc., a clinical stage biopharmaceutical company, is developing novel therapies for central nervous system (CNS) disorders. Its product candidate portfolio includes AXS-05, AXS-09, AXS-02, AXS-07, and AXS-06. AXS-05 is in the Phase III clinical trial in treatment resistant depression and in agitation associated with Alzheimer’s disease, as well as in the Phase II clinical trial for smoking cessation. AXS-02 is also in the Phase III clinical trial in knee osteoarthritis associated with bone marrow lesions pursuant to a special protocol assessment and in chronic low back pain associated with Modic changes. AXS-07 is in Phase I

Read More Here...

Bookmark the permalink.